Glenn Pomerantz is chief medical officer at Point32Health and is responsible for leading and advancing the organization’s clinical capabilities. In this role he oversees clinical innovation, quality and accreditation, medical policy, and the Harvard Pilgrim Health Care Institute, which includes the Department of Population Medicine at Harvard Medical School.
Dr. Pomerantz previously served as chief medical officer at C2i Genomics, a company that monitors cancer with a blood test that can better determine treatment, progression and recurrence. Prior to joining C2i Genomics, Dr. Pomerantz served as senior vice president of health services at Gateway Health in Pittsburgh, where he developed a 3–5 year network and clinical excellence strategy, which exceeded all state value-based payment goals. He also served as chief medical officer at Blue Cross and Blue Shield of Minnesota and Horizon Blue Cross Blue Shield of New Jersey, and as national medical director at Aetna and Cigna. In addition, Dr. Pomerantz previously served as an instructor of medicine at Harvard Medical School and spent thirteen years as a practicing physician.
Dr. Pomerantz holds a Doctor of Law degree from Boston School of Law, a Doctor of Medicine degree from the University of Miami Miller School of Medicine and a Bachelor of Science in chemistry from the University of Miami.